ACE-inhibitor use and the long-term risk of renal failure in diabetes

Kidney International
S SuissaA Kezouh

Abstract

The incidence of end-stage renal disease (ESRD) owing to diabetes has continued to increase despite the extensive use of angiotensin-converting enzyme (ACE) inhibitors to prevent diabetic nephropathy, primarily from evidence of short-term effectiveness. We assessed the long-term effect of ACE inhibitors on the risk of ESRD. We formed a population-based cohort of all diabetic patients treated with antihypertensive drugs in the Province of Saskatchewan, Canada, between 1982 and 1986. The patients were followed up to the end of 1997 to identify cases of end-stage renal failure. A nested case-control analysis was used with the controls matched to each case on age, diabetes type, and duration of follow-up. The cohort comprised 6102 subjects, of which the 102 cases who developed end-stage renal failure were matched to 4129 controls. Relative to thiazide diuretic use, the adjusted rate ratio of end-stage renal failure associated with the use of ACE inhibitors was 2.5 (95% confidence interval 1.3-4.7), whereas it was 0.8 (95% confidence interval 0.5-1.4) for beta-blockers and 0.7 (95% confidence interval 0.4-1.3) for calcium antagonists. The rate ratio of end-stage renal failure with the use of ACE inhibitors was 0.8 (95% confidence in...Continue Reading

References

May 1, 1992·Hypertension·M Epstein, J R Sowers
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Apr 7, 1990·BMJ : British Medical Journal·S BjörckM Aurell
Apr 1, 1983·Statistics in Medicine·O S Miettinen
May 1, 1982·Kidney International·E A Friedman
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y AokiS Pillai
Dec 30, 1993·The New England Journal of Medicine·W A RayJ Avorn
Mar 31, 1994·The New England Journal of Medicine·A Fournier, J D Lalau
Nov 11, 1993·The New England Journal of Medicine·G Remuzzi, P Ruggenenti
Oct 8, 1999·The New England Journal of Medicine·E Ritz, S R Orth
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm

❮ Previous
Next ❯

Citations

May 12, 2007·International Urology and Nephrology·Adrian CovicDavid J A Goldsmith
Jan 16, 2008·International Urology and Nephrology·Macaulay A C Onuigbo, Nnonyelum T C Onuigbo
Aug 16, 2008·International Urology and Nephrology·Kostas C Siamopoulos, Rigas G Kalaitzidis
Jan 15, 2011·Current Atherosclerosis Reports·Gianpaolo ReboldiPaolo Verdecchia
Jan 8, 2008·Current Hypertension Reports·Radica Alicic, Katherine R Tuttle
Mar 30, 2010·Nature Reviews. Nephrology·Takahiko Nakagawa
Feb 21, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gavin Y OuditJosef M Penninger
Oct 13, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Aimun K AhmedA Meguid El Nahas
Nov 8, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nagi AltemtamMeguid El Nahas
Apr 11, 2007·Current Opinion in Nephrology and Hypertension·Joshua I BarzilayBarry R Davis
Aug 19, 2010·International Journal of Clinical Practice·M A C Onuigbo
Dec 3, 2011·Nephron. Clinical Practice·Anderson Roman GonçalvesMeguid El Nahas
Feb 29, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Biff F Palmer
Dec 6, 2011·Current Cardiology Reports·Gianpaolo ReboldiPaolo Verdecchia
Mar 26, 2009·Der Internist·I Quack, L C Rump
Aug 21, 2014·Postgraduate Medicine·Ahmed H AbdelhafizJose M F de Oliveira
Sep 16, 2015·Journal of Clinical Medicine·Nicolas Roberto RoblesRoman Hernandez Gallego
Sep 4, 2008·Expert Opinion on Emerging Drugs·Su-Yen GohMark E Cooper
Oct 9, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Marit D Solbu, Alan G Jardine
Feb 23, 2007·Kidney International·S Hirsch
Jun 12, 2014·Kidney International·Gudbjörg AndrésdóttirPeter Rossing
Dec 1, 2012·Kidney International Supplements
Sep 22, 2006·Kidney International·M A C Onuigbo, N T C Onuigbo
Sep 22, 2006·Kidney International·S HiremathG A Knoll
Sep 22, 2006·Kidney International·I HammingG J Navis
Sep 22, 2006·Kidney International·K T WooC M Chan
Feb 9, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Faruk Turgut, Warren Kline Bolton
Jun 2, 2007·Néphrologie & thérapeutique·Jean-François BonneAlbert Fournier
Apr 10, 2007·Lancet·Roland E SchmiederBernhard M W Schmidt
Mar 8, 2007·The Journal of Clinical Hypertension·Shahzad Shafique, Aldo J Peixoto
Nov 26, 2009·Diabetes·Gavin Y OuditJames W Scholey
May 14, 2016·Internal Medicine Journal·W R Adam, J R Wright
Dec 23, 2009·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Nicolás Roberto RoblesJuan Jose Cubero
Feb 7, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·D N KoyeD J Magliano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.